Research programme: biodefence anti-infectives - MicrobiotixAlternative Names: Yersinia pestis cell surface plasminogen activator inhibitors - Microbiotix; Biodefence DNA helicase inhibitors - Microbiotix; Biodefence DNA replicase inhibitors - Microbiotix; Biodefense anti-infectives - Microbiotix; Quinolone-based inhibitors of BoNT/A LC - Microbiotix
Latest Information Update: 08 Jan 2013
At a glance
- Originator Microbiotix
- Class Imidazolines; Indoles; Nucleosides; Quinolones; Small molecules
- Mechanism of Action Adenosylhomocysteinase inhibitors; Botulinum toxin inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA topoisomerase IV inhibitors; DNA-directed DNA polymerase inhibitors; Metalloprotease inhibitors; Plasminogen activator inhibitors; Toll-like receptor 5 antagonists; Virus internalisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Anthrax; Botulism; Burkholderia infections; Ebola virus infections; Gram-negative infections; Yersinia infections
Most Recent Events
- 25 Sep 2012 Early research is ongoing in USA
- 01 Apr 2011 Early research in Botulism in USA (unspecified route)
- 01 Apr 2011 Microbiotix receives a Phase I SBIR grant from the US NIH to support development of small molecule, quinolone based inhibitors of Botulinum neurotoxin A for treatment of botulinum poisoning